Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
- Citation:
- J Clin Oncol vol 35 (15 suppl) abstr 1012
- Meeting Instance:
- ASCO 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2940
- Pharmas:
- Genentech, Roche
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Miguel Martin Sibylle Loibl Terry Hyslop Juan de la Haba-Rodriguez Bahriye Aktas Constance Cirrincione Eva Maria Carrasco Keyur Mehta William Thomas Barry Serafin Morales Lisa A. Carey Jose Angel Garcia Saenz Ann Partridge Noelia Martinez Olwen Mary Hahn Eric P. Winer Angel Guerrero Cliff Hudis Maribel Casas Maura N. Dickler
- Networks:
- LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, MONTEFIORE, PA121
- Study
- CALGB-40503
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: